SEC Tracker
Get the app

ImageneBio IMA

ImageneBio reports Q3 2026 financial results

ImageneBio (IMA) filed an 8-K with the SEC on Nov 9, 2026, 4:18 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Net loss of $15.6 million for Q3 2026, compared to $24.8 million in Q3 2025
  2. Cash position of $126.6 million as of September 30, 2026
  3. R&D expenses decreased to $11.3 million in Q3 2026 from $15.2 million in Q3 2025
  4. Phase 2b ADAPTIVE trial for atopic dermatitis expected to deliver topline data in Q4 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when ImageneBio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.